Zingenix: Gene Therapy for DMD
Zingenix, previously known as ILIT Bio Ventures Ltd is continuing its development programs, focusing on gene therapy for severe orphan disorders including DMD(Ducehenne Muscular Dystrophy) ,using artificial transcription factors technologies. The company has raised a seed round of funding and has been joined by Dr. Robert Heft from Canada who has been nominated as CEO and as a member of the board of directors. Dr. Heft is a leading scientist and entrepreneur. He served as President and CEO of Enobia Pharma Inc. (Montreal, Quebec) developing therapies for the treatment of serious genetic bone disorders . In February 2012 he led the sale of Enobia to Alexion Pharmaceuticals Inc. for $1.1 Billion, the largest-ever sale of a private, pre-commercial biopharmaceutical company. Prior to Enobia he held several senior positions with BioMarin Pharmaceutical Inc. (Novato, California) after selling the pharmaceutical assets of IBEX Pharmaceuticals Inc. (IBT:TSX, Montreal, Quebec) to BioMarin in 2001. Zingenix Team members are : Dr. Robert Heft- CEO; Dr. Yaffa Beck- CTO; Yoram Azulai- VP Finance; Avraham Landa-VP Business Development.